Business Context and Reporting Period
Company: Autonomix Medical, Inc. (AMIX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended September 30, 2025
Business Overview: A pre-revenue, clinical-stage medical device company developing a catheter-based platform for sensing and treating disorders of the peripheral nervous system, initially targeting pancreatic cancer pain. The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sept 30, 2025 | Six Months Ended Sept 30, 2025 | Balance Sheet (Sept 30, 2025) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(7,451) | $(10,788) | N/A |
| Operating Expenses | $7,534 | $10,955 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $7,477 |
| Working Capital | N/A | N/A | $6,406 |
| Total Liabilities | N/A | N/A | $1,487 |
| Accumulated Deficit | N/A | N/A | $(61,167) |
Cash Flow (Six Months Ended Sept 30, 2025):
- Net cash used in operating activities: $(6,421) thousand
- Net cash provided by financing activities: $4,762 thousand (primarily from stock issuance and warrant inducements)
- Net decrease in cash: $(1,659) thousand
Material Changes vs. Prior Period
- Expense Surge: Total operating expenses increased 166% for the three months ended September 30, 2025, compared to the same period in 2024 ($7.5M vs. $2.8M). This was driven by a 211% increase in General and Administrative (G&A) expenses and a 102% increase in Research and Development (R&D).
- Stock-Based Compensation: A significant non-cash charge of $3.7 million was recognized in the quarter due to the acceleration of stock-based compensation following the cancellation of stock options for certain employees and board members in exchange for severance agreements.
- Capital Structure: The company significantly increased its share count through ATM sales, warrant exercises, and a warrant inducement transaction, raising approximately $5.1 million in gross proceeds during the six-month period.
- EPS Correction: The company corrected an immaterial error in prior period EPS calculations related to the exclusion of certain low-exercise-price warrants, revising the weighted average shares outstanding for the prior year.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management states that current cash resources ($7.5M) are sufficient to fund operations only into the third calendar quarter of 2026. The filing explicitly raises substantial doubt about the company's ability to continue as a going concern without additional financing.
- Capital Needs: The company estimates it requires an additional $30 million to $36 million to fund operations through the commercialization of its first indication.
- Financing Activities:
- Entered a Purchase Agreement with Lincoln Park Capital Fund, LLC for up to $15.0 million in equity sales.
- Increased the capacity of its At-Market (ATM) sales agreement to $3.5 million.
- Completed a warrant inducement in July 2025, reducing exercise prices and issuing new warrants to raise approximately $2.5 million.
- Operational Progress: Completed the final design review of its intravascular nerve-sensing catheter. Reported positive post-hoc data from its first-in-human proof-of-concept study in pancreatic cancer pain (66% mean pain reduction among responders). Initiated a follow-on study (PoC 2).
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting due to a lack of segregation of duties and limited staffing. Management concluded disclosure controls were not effective as of September 30, 2025.
- Subsequent Events: Stockholders approved a potential reverse stock split (1-for-2 to 1-for-25) and the issuance of more than 20% of outstanding stock under the Lincoln Park agreement.
Key Facts for Investor Verification
- Cash Runway: Verify the timeline for cash exhaustion (Q3 2026) against the burn rate and the likelihood of securing the estimated $30M-$36M needed for commercialization.
- Dilution Risk: Assess the impact of the recent warrant inducement, ATM sales, and the potential reverse stock split on existing shareholder value.
- Internal Controls: Monitor the remediation plan for the material weaknesses in financial reporting and segregation of duties.
- Clinical Milestones: Track the progress of the PoC 2 study and the timeline for regulatory clearance (FDA) for the nerve-sensing catheter.
- Financing Execution: Confirm the actual utilization of the Lincoln Park Purchase Agreement and ATM facility to bridge the funding gap.